OmniAb Investor Day Adds Platforms But Leaves Core Revenue Questions Unanswered

What happened

OmniAb's investor day outlined expanded royalty partnerships, xPloration commercialization, and entry into peptide discovery via OmniTides. However, xPloration revenue remains minimal at $0.8 million from a single instrument sale in fiscal 2025, and management concedes partner counts do not guarantee revenue. The new OmniTides platform adds unproven scope at a time when cash is guided to fall to $30-35 million by end-2026 against a $100 million ATM and prior dilution. Partner-dependent catalysts like Merck KGaA's Phase III start and Immunovant's topline are outside OmniAb's control and may not trigger near-term economics. Until xPloration shows scaled placements and partner milestones convert into reported revenue, the stock warrants a wait-and-see approach.

Implication

For investors, OmniTides is a speculative addition that may consume cash without near-term revenue, competing with core platform funding. xPloration remains the critical test: without a disclosed install base and recurring revenue, its contribution is negligible. Partner catalysts could provide upside, but their timing and terms are opaque, so treat them as options rather than certainties. Given cash burn projections and dilution risk, positions should be modest and monitored for financing actions. The next quarterly report will be pivotal: if xPloration revenue fails to grow or guidance slips, the dilution overhang may intensify.

Thesis delta

The OmniTides launch expands the platform portfolio but does not address the immediate need for xPloration revenue scaling or milestone realization. The fundamental thesis is unchanged: OmniAb remains a cash-burning discovery platform where equity value hinges on partner milestone conversion and xPloration adoption, with significant dilution risk if cash targets are missed. The WAIT rating and conviction of 3 are maintained, with checkpoints unchanged.